To deliver personalized medicine to the long tail of patients left behind by traditional drug development, starting with chronic, hard-to-treat infections like Mycobacterium abscessus complex pulmonary disease (MABC-PD). We combine agentic AI, robotic manufacturing, and bacteriophages to tailor each therapy to the patient.
Explore our phage therapy expanded access program
Technologies for generating superphages and optimizing phage cocktails are poised to overcome antibiotic resistance and resolve microbiome dysbiosis
Phage Therapy Today Podcast Episode
